Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.

[1]  Jennifer L. Harris,et al.  Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1. , 2005, Bioorganic & medicinal chemistry letters.

[2]  R. Thurmond,et al.  Cathepsin S inhibitors as novel immunomodulators. , 2005, Current opinion in investigational drugs.

[3]  P. Christadoss,et al.  Cathepsin S Is Required for Murine Autoimmune Myasthenia Gravis Pathogenesis1 , 2005, The Journal of Immunology.

[4]  D. Spero,et al.  Cysteine protease cathepsin S as a key step in antigen presentation. , 2004, Drug news & perspectives.

[5]  Vincent Leroy,et al.  Cathepsin S inhibitors , 2004 .

[6]  E. Altmann,et al.  Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1' substituents. , 2003, Bioorganic & medicinal chemistry letters.

[7]  Traian Sulea,et al.  Specificity determinants of human cathepsin s revealed by crystal structures of complexes. , 2003, Biochemistry.

[8]  A. Rudensky,et al.  Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. , 1999, Immunity.

[9]  Munir Pirmohamed,et al.  The role of metabolic activation in drug-induced hepatotoxicity. , 2005, Annual review of pharmacology and toxicology.

[10]  N. Kitteringham,et al.  Metabolism of fluorine-containing drugs. , 2001, Annual review of pharmacology and toxicology.

[11]  J. Vervoort,et al.  Bioactivation of 4-fluorinated anilines to benzoquinoneimines as primary reaction products. , 1991, Chemico-biological interactions.